Gralise and Skin discoloration - a phase IV clinical study of FDA data

Summary:

Skin discoloration is reported as a side effect among people who take Gralise (gabapentin), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Klonopin, and have Pain.

The phase IV clinical study analyzes which people have Skin discoloration when taking Gralise. It is created by eHealthMe based on reports of 4,175 people who have side effects when taking Gralise from the FDA, and is updated regularly.

What is Gralise?

Gralise has active ingredients of gabapentin. It is often used in neuralgia. eHealthMe is studying from 4,282 Gralise users. Check the latest studies of Gralise.

What is Skin discoloration?

Skin discoloration is found to be associated with 1,716 drugs and 1,590 conditions by eHealthMe. Check the latest studies of Skin discoloration.

On Jul, 20, 2026

4,175 people reported to have side effects when taking Gralise.
Among them, 14 people (0.34%) have Skin discoloration.

Among these 14 people:

How long have people been on Gralise when they have Skin discoloration? *

What is the gender of people who have Skin discoloration when taking Gralise? *

female: 41.67 %
male: 58.33 %

What is the age of people who have Skin discoloration when taking Gralise? *

What are other drugs people take besides Gralise? *

What are other side effects people have besides Skin discoloration? *

Rashes (redness): 7 people, 50.00%
Wound: 6 people, 42.86%
Adverse Event: 6 people, 42.86%
Emotional Disorder: 6 people, 42.86%
Head Injury: 6 people, 42.86%
Hernia (hernia happens when part of an internal organ or tissue bulges through a weak area of muscle): 6 people, 42.86%
Insomnia (sleeplessness): 6 people, 42.86%
Loss Of Consciousness: 6 people, 42.86%
Memory Loss: 6 people, 42.86%
Increased Tendency To Bruise (increased tendency to injure the underlying soft tissue or bone): 6 people, 42.86%

What are the existing conditions these people have? *

Pain: 7 people, 50.00%
Waldenstrom's Macroglobulinaemia (cancer affects small lymphocytes (white blood cells)): 6 people, 42.86%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 6 people, 42.86%
Non-Hodgkin's Lymphoma (malignant (cancer) cells form in the lymph system): 6 people, 42.86%
Burkitt Lymphoma (cancer of the lymphatic system): 6 people, 42.86%
Breakthrough Pain: 6 people, 42.86%
Abdominal Pain: 6 people, 42.86%
Skin Disorder (skin disease): 1 person, 7.14%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Gralise and have Skin discoloration?

- Check whether Skin discoloration is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Gralise:

Gralise (4,282 reports)

Browse all side effects of Gralise:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Skin discoloration:

Skin discoloration (1,716 drugs)

Browse all the conditions that are associated with Skin discoloration:

Skin discoloration (1,590 conditions)

Related publications that referenced our studies

de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .
de Landaluce, L. O., Carbonell, P., Asensio, C., Escoda, N., López, P., & Laporte, J. R. , "Gabapentin and Pregabalin and Risk of Atrial Fibrillation in the Elderly: A Population-Based Cohort Study in an Electronic Prescription Database", Drug safety, 2018 Jan .
Scarff JR, "The Potential for Somnambulism Associated with Gabapentin", The Internet Journal of Psychiatry, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on gabapentin (the active ingredients of Gralise) and Gralise (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.